ClearBridge Investments
KROS icon

ClearBridge Investments’s Keros Therapeutics KROS Stock Holding History

ClearBridge Investments’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-156,724
Closed -$1.6M – 727
2025
Q1 		$1.6M Sell
156,724
-33,340
-18% -$387K ﹤0.01% 618
2024
Q4 		$3.01M Buy
+190,064
New +$9.88M ﹤0.01% 603

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ClearBridge Investments's KROS Position: Q2 2025 in Review

ClearBridge Investments sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 156,724 shares — an estimated $1.6M sold.

ClearBridge Investments first reported a position in KROS in Q4 2024 and held it in 2 quarters. The position peaked at $3.01M in Q4 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • ClearBridge Investments reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ClearBridge Investments sold 156,724 Keros Therapeutics shares in Q2 2025, an estimated $1.6M.
  • ClearBridge Investments first reported a position in Keros Therapeutics in Q4 2024 and held it in 2 quarters.
  • ClearBridge Investments's Keros Therapeutics position peaked at $3.01M in Q4 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on ClearBridge Investments's 13F filing for Q2 2025, filed 12 Aug 2025.